19h agoSeeking AlphaBULLISH 58Earnings
ADARx Pharmaceuticals reports Q3 results
ADARx Pharmaceuticals narrows Q3 GAAP loss per share 6% year over year to $1.74, while collaboration revenue rises 43% to $2.2 million.
Archived explainer. For the current picture see today's ADRX page.
Why Is ADARX PHARMACEUTICAL (ADRX) Stock Up Today?
By the Top Tier Newswire AI Desk · November 13, 2026 at 5:05 AM ET · reviewed against 3 wire stories
ADARX PHARMACEUTICAL (ADRX) is up +12.11% in the latest session. Our newswire has captured 3 stories on ADRX across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Adarx Pharmaceuticals (ADRX) shares rose 12.11% to $14.91, driven by the release of third-quarter financial results and the initiation of coverage by major investment banks. The company reported a narrowed loss per share and increased collaboration revenue, while analysts assigned positive ratings and price targets.
What Happened
Adarx Pharmaceuticals filed a Form 8-K on November 12, 2026, disclosing its third-quarter 2026 results. The company reported a GAAP loss per share of $1.74, a 6% improvement from the $1.85 loss per share recorded in the same period last year. Collaboration revenue increased 43% year over year to $2.2 million.
Two major banks initiated coverage on the stock following the earnings release. TD Cowen initiated coverage with a Buy rating. JP Morgan initiated coverage with an Overweight rating and set a price target of $38. These actions provided fresh institutional perspective on the company’s valuation and growth trajectory.
What The Data Shows
The stock’s market capitalization stands at $1.5 billion. Over the past 52 weeks, the stock traded within a range of $12.50 to $23.21. On November 12, the stock printed 14 fresh 52-week highs and 3 fresh 52-week lows.
Despite the strong session, the stock is down 7.3% over the last eight sessions, moving from $16.09 to $14.91. Insider activity has been notably bullish, with five buys totaling $87.7 million and no sells in the last 90 days. Recent Form 4 filings show purchases by Orbimed Advisors LLC, Gordon Carl L, and Sr One Capital Management, LLC on September 28, 2026.
What To Watch
Investors will monitor how the stock reacts to the new analyst coverage and whether the price target of $38 from JP Morgan influences near-term trading. The upcoming earnings date is not specified in the provided data, so attention remains on the initial market absorption of the third-quarter results and the new institutional ratings.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ADRX by the numbers
Last: $14.91Session: +12.11%7 sessions: -5.08%Coverage: 3 stories / 3 sourcesAI sentiment: 55/100 (mixed)Mkt cap: $1.5B52w: $12.50 to $23.21
The headlines behind the move
1d agoThe FlyBULLISH 56Earnings
ADARx Pharmaceuticals reports Q3 EPS ($1.74) vs. ($1.85) last year
1d agoSEC 8-KNEUTRAL 50General
ADARx Pharmaceuticals, Inc. (ADRX) files 8-K: Items 2.02, 7.01, 9.01
Filed: 2026-11-12 AccNo: 0001193125-26-458321 Size: 17 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ADRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ADRX move explainers: 2026-11-13